



Antimicrobial Resistance and Healthcare Associated Infections

Guest Editors:

Prof. Dr. Thaís Guimarães

1. Infection Control Department,
Instituto Central, Hospital das
Clínicas, University of São Paulo,
São Paulo, Brazil

2. Infection Control Department,
Hospital do Servidor Público
Estadual de São Paulo, São
Paulo 04039-000, Brazil

Prof. Dr. Sílvia Figueiredo Costa

1. Instituto de Medicina Tropical,
Faculdade de Medicina,
Universidade de São Paulo, Av.
Dr. Enéas Carvalho de Aguiar,
470, São Paulo 05403-000, Brazil

2. Department of Infectious
Diseases, Faculdade de Medicina,
Universidade de São Paulo, São
Paulo, SP, Brazil

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

Antimicrobial resistance (AMR) is a global health and development threat that requires urgent multisector action in order to achieve goals and to implement effective prevention measures.

Healthcare-associated infections (HCAI) due to microorganisms that are antimicrobial resistant are today one of the most important challenges in modern medicine. One major preventive goal is preventing infections and maintaining optimal antimicrobial treatment, so that we could consequently prevent all avoidable HCAI but especially make sure that non-avoidable infections are at the very least treatable.

Misuse and overuse of antimicrobials are the main drivers in the development of multidrug-resistant pathogens. In the same manner, inadequate infection prevention and control promotes the spread of these microorganisms. In addition, the costs of AMR to the economy are significant, and the same is true for death, disability, prolonged illness resulting in longer hospital stays, and the need for more expensive medicines and financial challenges that have a negative impact both at an individual and social level.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)